Thomas P. Cirrito
15 Papers
103 Citations
Thomas P. Cirrito is an academic researcher. The author has contributed to research in topics: Cancer stem cell & Cancer. The author has an hindex of 6, co-authored 15 publications.
Chat about Author
Papers
Patent
Monitoring cancer stem cells
Thomas P. Cirrito,Ivan Bergstein +1 more
- 07 Sep 2007
TL;DR: In this article, a method for monitoring the amount of cancer stem cells in patients undergoing cancer therapy to determine whether the cancer therapy is an effective cancer therapy was presented. But, this method is not suitable for the treatment of cancer.
34
Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies.
Arthur E. Frankel,Marina Konopleva,Donna E. Hogge,David A. Rizzieri,Christopher L. Brooks,Thomas P. Cirrito,Steven M. Kornblau,Gautam Borthakur,Carol Bivins,Guillermo Garcia-Manero,Farhad Ravandi,Tapan M. Kadia,Michael Andreeff,Jorge E. Cortes,Kenneth Hoberman,Michael Szarek,Ivan Bergstein,Hagop M. Kantarjian,Eric K. Rowinsky +18 more
TL;DR: A single cycle of SL-401 demonstrated single agent activity in relapsed or refractory AML paties, and the maximum tolerated dose (MTD) and antitumor activity were evaluated.
31
Patent
Cancer Therapy With Cantharidin And Cantharidin Analogs
Thomas P. Cirrito,Ivan Bergstein +1 more
- 07 Sep 2007
TL;DR: In this article, the authors provided methods for treating cancer in a patient, comprising administration of a therapeutically effective regimen of cantharidin or cantharaidin analog of formula of formula I, II or III wherein R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, A, Y and Z are as set forth herein, or a pharmaceutically acceptable salt thereof.
22
Patent
Cancer stem cell-targeted cancer therapy
Thomas P. Cirrito,Ivan Bergstein +1 more
- 07 Sep 2007
TL;DR: In this article, a method for stabilizing, reducing, or eliminating cancer cells is presented, which can be administered at a lower dose than currently used or known to one of skill in the art.
16
SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML
Marina Konopleva,Donna E. Hogge,David A. Rizzieri,Thomas P. Cirrito,Steven M. Kornblau,Gautam Borthakur,Carol Bivins,Guillermo Garcia-Manero,Tapan M. Kadia,Farhad Ravandi,Michael Andreeff,Jorge E. Cortes,Kenneth Hoberman,Michael Szarek,Eric K. Rowinsky,Ivan Bergstein,Hagop M. Kantarjian,Arthur E. Frankel +17 more
TL;DR: SL-401 demonstrated single agent anti-tumor activity and was well tolerated in patients with advanced AML; improved survival was observed among patients who received a single cycle of SL-401 as ≥3rd line treatment, a disease setting in which there is no standard therapy.
15